Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/395
A61K-039/145
A61K-039/39
A61K-009/127
A61K-039/07
A61K-039/02
A61K-039/12
A61K-039/00
출원번호
US-0347928
(2012-10-05)
등록번호
US-10105435
(2018-10-23)
국제출원번호
PCT/CA2012/050705
(2012-10-05)
국제공개번호
WO2013/049941
(2013-04-11)
발명자
/ 주소
Mansour, Marc
MacDonald, Lisa Diana
Weir, Genevieve Mary
Sammatur, Leeladhar
Sharp, Kendall
출원인 / 주소
IMMUNOVACCINE TECHNOLOGIES INC.
대리인 / 주소
Troutman Sanders LLP
인용정보
피인용 횟수 :
0인용 특허 :
88
초록▼
The invention provides compositions comprising liposomes, an antigen capable of inducing a humoral immune response, a carrier comprising a continuous phase of a hydrophobic substance, and an adjuvant that activates or increases the activity of TLR2. The invention also provides uses for such composit
The invention provides compositions comprising liposomes, an antigen capable of inducing a humoral immune response, a carrier comprising a continuous phase of a hydrophobic substance, and an adjuvant that activates or increases the activity of TLR2. The invention also provides uses for such compositions in inducing a humoral response and methods for their use in the treatment of a disease, disorder or ailment ameliorated by a humoral immune response.
대표청구항▼
1. A method for vaccinating against an infectious disease by inducing a protective humoral immune response against a pathogen of the infectious disease, said method comprising administering to a subject an effective amount of a water-free composition comprising an adjuvant that activates or increase
1. A method for vaccinating against an infectious disease by inducing a protective humoral immune response against a pathogen of the infectious disease, said method comprising administering to a subject an effective amount of a water-free composition comprising an adjuvant that activates or increases the activity of toll-like receptor 2 (TLR2) and dehydrated liposomes with an encapsulated antigen of the pathogen, reconstituted in a mineral oil carrier, wherein the antigen comprises a B cell epitope and is capable of inducing a humoral immune response; wherein the adjuvant comprises PAM2Cys-Ser-(Lys)4 (SEQ ID NO: 1) or PAM3Cys-Ser-(Lys)4 (SEQ ID NO:1); and wherein the antigen is not coupled covalently or non-covalently to the adjuvant. 2. The method of claim 1, wherein the adjuvant activates or increases the activity of TLR2 by interacting with a TLR2 dimer of TLR1/2 or TLR2/6. 3. The method of claim 1, wherein the adjuvant is PAM2Cys-Ser-(Lys)4. 4. The method of claim 1, wherein the adjuvant is PAM3Cys-Ser-(Lys) 4. 5. The method of claim 1, wherein the antigen is a polypeptide or a carbohydrate. 6. The method of claim 1, wherein the B cell epitope is derived from a virus or bacteria. 7. The method of claim 6, wherein the B cell epitope is derived from influenza virus, Bordetella pertussi, or Bacillus anthracis. 8. The method of claim 7, wherein the B cell epitope is an epitope of a hemagglutinin protein of H5N1 influenza virus, an epitope of pertussis toxoid protein, or an epitope of an anthrax recombinant protective antigen. 9. The method of claim 1, wherein both the antigen and the adjuvant are encapsulated in the dehydrated liposomes reconstituted in the mineral oil carrier. 10. The method of claim 1, wherein the liposomes are non-cationic liposomes, wherein the lipids of the liposomes consist of neutral lipids, negatively charged lipids or a mixture thereof. 11. The method of claim 1, wherein the composition is capable of inducing a humoral immune response with a single dose. 12. The method of claim 1, wherein the infectious disease is selected from the group consisting of influenza, a respiratory tract infection or lung infection caused by respiratory syncytial virus, whooping cough, anthrax, and malaria. 13. The method of claim 1, wherein the liposomes are comprised of phospholipids and cholesterol. 14. The method of claim 1, wherein the carrier is a mannide oleate in mineral oil solution. 15. The method of claim 14, wherein the carrier is Montanide® ISA 51. 16. The method of claim 1, wherein the antigen is selected from the group consisting of H5N1 recombinant hemagglutinin protein, pertussis toxoid protein, anthrax recombinant Protective Antigen and heat inactivated Influenza strain A/PR/8/34 (H1N1). 17. The method of claim 1, wherein the liposomes comprise S100 lecithin and cholesterol or dioleoyl-phosphatidylcholine (DOPC) and cholesterol; the carrier is Montanide® ISA 51; and the adjuvant is PAM3Cys-Ser-(Lys) 4 (SEQ ID NO:1). 18. The method of claim 17, wherein the antigen is selected from the group consisting of H5N1 recombinant hemagglutinin protein, pertussis toxoid protein, anthrax recombinant Protective Antigen and heat inactivated Influenza strain A/PR/8/34 (H1N1). 19. The method of claim 1, wherein the liposomes are dehydrated by lyophilization. 20. The method of claim 9, wherein the liposomes are dehydrated by lyophilization.
Dunbar Bonnie S. (2001 Holcombe #2302 Houston TX 77030) Prasad Sarvamangala V. (5123 Jackwood Houston TX 77096), Contraceptive vaccine comprising a glycosylated 55 kD zona pellucida protein immunogen and method of use of the same in.
Yves Delmotte BE; Arnold Bilstad ; David Amrani ; James DiOrio ; Atif M. Yardimci ; David W. Pennington ; James S. Slepicka ; Cristina Stadler, Fibrin delivery device and method for forming fibrin on a surface.
Koelle,David M.; Hosken,Nancy A.; Posavad,Christine M.; Chen,Hongbo; McGowan,Patrick, Immunologically significant herpes simplex virus antigens and methods for using same.
Sette,Alessandro; Sidney,John; Southwood,Scott; Chesnut,Robert; Celis,Esteban; Grey,Howard M., Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions.
Fountain Michael W. (Plainsboro NJ) Weiss Steven J. (Lawrenceville NJ) Kearns John J. (Princeton NJ) Weiner Alan L. (Plainsboro NJ) Popescu Mircea C. (Plainsboro NJ), Lipid matrix carriers for use in drug delivery systems.
Woodle Martin C. (Menlo Park CA) Martin Francis J. (San Francisco CA) Yau-Young Annie (Los Altos CA) Redemann Carl T. (Walnut Creek CA), Liposomes with enhanced circulation time.
Howard Sands ; Awadhesh Mishra CA, Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin.
Brown Robert,CAX ; Mezei Michael,CAX ; Pohajdak Bill,CAX ; Kimmins Warwick Charles,CAX, Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome a.
Brown Robert,CAX ; Mezei Michael,CAX ; Mezei Catherine,CAX ; Pohajdak Bill,CAX ; Kimmins Warwick Charles,CAX, Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and adjuvant.
Popescu Mircea C. ; Weiner Alan L. ; Recine Marie S. ; Janoff Andrew S. ; Estis Leonard ; Keyes Lynn D. ; Alving Carl R., Potentiation of immune responses with liposomal adjuvants.
Leveugle, Beatrice; Madiyalakan, Ragupathy; Noujaim, Antoine A.; Schultes, Birgit, Reagents and methods for inducing an immune response to prostate specific antigen.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.